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Costimulation blockade (CoB) via belatacept is a lower-morbidity alternative to calcineurin inhibitor (CNI)-based immunosuppression. However, it has higher rates of early acute rejection. These early rejections are mediated in part by memory T cells, which have reduced dependence on the pathway targeted by belatacept and increased adhesion molecule expression. One such molecule is leukocyte function antigen (LFA)-1. LFA-1 exists in two forms: a commonly expressed, low-affinity form and a transient, high-affinity form, expressed only during activation. We have shown that antibodies reactive with LFA-1 regardless of its configuration are effective in eliminating memory T cells but at the cost of impaired protective immunity. Here we test two novel agents, leukotoxin A and AL-579, each of which targets the high-affinity form of LFA-1, to determine whether this more precise targeting prevents belatacept-resistant rejection. Despite evidence of ex vivo and in vivo ligand-specific activity, neither agent when combined with belatacept proved superior to belatacept monotherapy. Leukotoxin A approached a ceiling of toxicity before efficacy, while AL-579 failed to significantly alter the peripheral immune response. These data, and prior studies, suggest that LFA-1 blockade may not be a suitable adjuvant agent for CoB-resistant rejection.
Introduction
Renal transplantation remains the most effective means of treating end-stage renal disease, improving morbidity and mortality compared with the alternative of dialysis (1) . The success of transplantation requires long-term immunosuppression largely based on calcineurin inhibitors (CNIs), which can often result in significant side effects including nephrotoxicity. These toxicities from conventional immunosuppression are due to their effects on broader molecular pathways not isolated to lymphocyte-specific mechanisms. T cell costimulation blockade (CoB) provides a lymphocyte-specific target for the suppression of alloreactive responses and is available for clinical transplantation through the CD28-B7 pathway inhibitor belatacept. The initial clinical studies of belatacept demonstrated efficacy, absent many of the offtarget side effects typically seen with CNIs (2-4). However, widespread application of belatacept in the clinic has been hesitant due to increased rates of aggressive early acute rejection (5) . The etiology of CoB-resistant rejection (CoBRR) is attributed at least in part to memory T cells, which, during their development and expansion, downregulate CD28 and are thereby indifferent to CD28: B7 blockade (6, 7) . In addition, T effector memory (T EM ) cells possess an increased potential to proliferate and mediate immune effector functions such as leukocyte adhesion and diapedesis-teleologic attributes that are invariably deleterious to the allograft (6, 8) . The favorable side effect profile of belatacept has given impetus to better understanding memory T cells and the development of adjuvant therapies for use with belatacept.
The functional requirements of T EM cells lead to a unique surface protein phenotype with increased expression of CD2 and adhesion molecules such as very late antigen-4 (VLA-4) and leukocyte function antigen (LFA)-1 (7, 9) . A recent report demonstrated a novel CD4 + CD57 + PD-1 -T cell subset phenotype associated with CoBRR in renal transplant patients that also expressed these adhesion molecules in greater quantity (10) . Indeed, the differential expression of these markers on the suspected T cell subsets in CoBRR offers unique opportunities for adjuvant therapy, supported in proof of concept by several murine studies (11) (12) (13) (14) (15) . We have previously studied agents targeting memory T cell markers as adjuvant therapy to CoB in nonhuman primate (NHP) models. Alefacept, a depleting agent targeting CD2, effectively reduced T EM cells in circulation (9) and variably prolonged allograft survival in kidney, islet, and vascularized composite allograft models but at the cost of a significant reduction in protective immunity (16) (17) (18) . The use of LFA-1 blockade to improve clinical islet allotransplant outcomes (19, 20) and in an NHP model (21) supports the conceptual efficacy in other models of transplantation. We recently reported our experience inhibiting LFA-1 with belatacept in an NHP renal transplant model. This approach did not improve allograft survival over belatacept alone and, like CD2-specific blockade, resulted in diminished protective immunity leading to increased cytomegalovirus (CMV) reactivation (22) .
Integrins such as LFA-1 require specific control of receptor-ligand affinities based on functional need. In the case of LFA-1, three conformational states are defined, of which only one has high affinity (HA) for ligand (23) . The generally expressed closed conformations prevent unnecessary binding to intercellular adhesion molecules (ICAMs), while the open, HA form is expressed transiently on chemokine-mediated activation (24) . Dynamic change in LFA-1 structure has been demonstrated to be involved in the immunologic synapse, chemokine-induced activation, and tissue migration (25) (26) (27) . Our prior study did not so much indicate that there was no effect of LFA-1 blockade but rather that the effect was so global that it overly impaired protective immunity; the safety signature capped out before its efficacy signature. We hypothesize that specifically targeting the HA conformation of LFA-1 would more precisely target acutely activated T EM cells, reduce their access to the allograft, and potentially limit the detrimental effects on protective immunity.
Leukotoxin A (LtxA) is a protein isolated from Aggregatibacter actinomycetemcomitans (28) that is more selective for the HA conformation of LFA-1 and induces cell death (29) . AL-579 is a ligand mimetic antibody that specifically binds to the HA LFA-1 conformation but does not induce cell death (30, 31) . The fundamental rationale in these experiments is that more precise targeting of HA LFA-1 will act only at the site of lymphocyte activation and not globally disrupt all lymphocyte trafficking. This could allow for a focused therapeutic effect, likely within the allograft, without a global effect on established protective immunity. In these studies, we incorporate selective targeting of the activated conformation of LFA-1 through either depletion with LTxA or blockade with AL-579 in combination with belatacept. We demonstrate that despite evidence of in vitro and in vivo efficacy, these agents ultimately do not mitigate CoBRR.
Materials and Methods

In vitro assays
Peripheral blood mononuclear cells (PBMCs) were isolated from cell-processing tubes (BD Biosciences, San Jose, CA) from three rhesus macaques and suspended in RPMI supplemented with 10% FBS, 1% HEPES buffer, glutamine, and penicillin/streptomycin at a concentration of 10 6 cells/mL. LtxA was added at concentrations of 1 ng/mL, 10 ng/mL, 100 ng/mL, 1 lg/mL, or 10 lg/mL, and cells were incubated for 1.5 h at 37°C. Cells were then washed and plated in a 96-well round-bottom plate with 10 6 cells/well. Cells were resuspended in 100 lL of annexin V buffer (BD Biosciences) per the manufacturer's instructions and stained with surface antibodies for 15 min at room temperature. The surface staining consisted of antibodies against CD3, CD4, CD8, CD56, CD11a, CD16, CD95, CD28, and CD20. The cells were then washed twice with annexin V buffer with the addition of 7AAD after the final wash and immediately acquired on the flow cytometer. Heat-killed cells were used as a compensation control for 7AAD staining. For experiments using activated cells, surface staining was done before incubation with the same varying concentrations of LtxA, with or without the addition of phorbol 12-myristate 13-acetate (PMA) and ionomycin.
Development of LtxA and AL-579
LtxA was purified from culture supernatants of A. actinomycetemcomitans strain NJ4500 as described previously (32, 33) . The activity was confirmed against the THP-1 leukemia cell line. AL-579 is an HA variant of AL-57 that contains further substitutions to make it more drug like (Figure S1 ) (31, 34) . The heavy and light chains of antibody AL-579 were subcloned into expression vectors and used to cotransduce Chinese hamster ovary cells via electroporation. An oligoclonal pool of transduced cells was grown in serum-free, chemically defined medium, and secreted antibody was purified through protein A affinity chromatography. The purified antibody was diafiltered into citrate buffer; endotoxin levels were confirmed to be < 1 endotoxin unit/mg.
Rhesus renal transplantation and monitoring
All experiments performed in this study were conducted with the approval of the Emory University or Duke University Institutional Animal Care and Use Committee and in adherence with the principles laid out in the "Guide for the Care and Use of Laboratory Animals" (Institute of Laboratory Animal Resources, National Research Council, DHHS). Rhesus macaques (Macaca mulatta) were obtained from breeding colonies at AlphaGenesis, Inc. (Yemassee, SC) for both Emory University and Duke University or Yerkes National Primate Research Center (Lawrenceville, GA) for Emory University. Donor-recipient pairs were determined primarily through MHC disparity with a minimum of three major antigen mismatches and secondarily by similar size. MHC typing for both class I and class II was performed with 454 pyrosequencing (University of Wisconsin, Madison, WI). Transplantation was performed in a domino fashion to maximize the utility of the available animals, with each animal serving as a kidney donor before receiving a transplant, as described previously (16, 22, 35) . Left donor nephrectomy was performed at least 3 weeks before transplantation. A right nephrectomy was simultaneously conducted after implantation to leave each recipient entirely dependent on the allograft. Posttransplantation monitoring consisted of daily clinical assessment by the veterinary staff, as well as laboratory studies that included serum chemistry and complete blood count assessments performed 2-4 times monthly, or more often if dictated by clinical condition. Rhesus CMV was monitored with every blood draw and when clinically indicated using quantitative polymerase chain reaction. CMV prophylaxis was initiated at the time of transplantation and consisted of valganciclovir 60 mg twice daily, with viral copies > 10 000/mL treated with the addition of intramuscular ganciclovir 5-7.5 mg/kg twice daily. Experimental end point was determined by significant increase in serum creatinine confirmed over 2 days. Humane end points were implemented when necessary after consultation with the veterinary staff.
Transplant groups and immunosuppression
Transplantations incorporating LtxA-based regimens were conducted at Emory University. Three animals received LtxA monotherapy with 15 µg/ kg intravenously given on the day of transplantation and 2.5, 10, or 15 µg/kg (each n = 1) given on postoperative days (PODs) 3 and 7. Different doses of maintenance drug were used in an effort to identify a potential therapeutic dose. Animals receiving belatacept monotherapy (n = 3) were given belatacept 20 mg/kg on the day of transplantation; PODs 3, 7, 14, 21, and 28; and then every 2 weeks until POD 182, and then monthly. Eight animals in total received combined LtxA and belatacept.
LtxA was given at a high dose of 75 µg/kg on the day of transplantation and PODs 3 and 7 (n = 2), an intermediate dose of 25 µg/kg on the day of transplantation and on PODs 3 and 7 (n = 3), and a low dose of 15 µg/ kg on the day of transplantation and on PODs 3 and 7 (n = 3). All recipients in this study received a single dose of methylprednisolone 15 mg/kg intraoperatively before graft implantation.
The cohort for AL-579-based regimens were performed at Duke University, with the exception of one AL-579 with belatacept transplantation performed at Emory University. The control group of transplant recipients for AL-579 received belatacept at 20 mg/kg on the day of transplantation; PODs 3, 7, 14, 21, and 28; and then every 2 weeks (no change in frequency at POD 182, n = 4). The experimental group to this belatacept regimen was given AL-579 as a taper, starting with 20 mg/kg on PODs 0, 3, 7,10, and 14; then 10 mg/kg twice weekly until POD 31; and then 5 mg/kg twice weekly until POD 56 (n = 4). All recipients in this study received a single dose of methylprednisolone 15 mg/kg intraoperatively before graft implantation. Figure 1 illustrates the immunosuppressive regimens described above.
Polychromatic flow cytometry
PBMCs were isolated from transplant recipients immediately before transplantation (POD 0) and immediately before every belatacept infusion as outlined. After washing with PBS and lysis of red blood cells, cells were stained with the following antibodies: CD3, CD4, CD2, CD28, CD95, CD11a, CD16, CD20, CD56, CD45, FoxP3, CD25, CD127, Ki67, and Bcl2. At the time of rejection and recipient euthanasia, PBMCs were also collected, in addition to lymph nodes and spleen tissue. Cells were isolated from these lymphoid organs through mechanical disassociation and passage of cells though a 70-µm filter. The resulting cells were lysed and stained for flow cytometry by using the methods just described.
Histology
At the time of recipient end point, lymph nodes, spleen, and the allograft were collected in 10% formalin for histologic evaluation. These samples were embedded in paraffin with subsequent sectioning and hematoxylin and eosin staining. Staining for HA LFA-1 was performed on specimens from our previous NHP transplant studies (35) . Samples were identified and then stained after deparaffinization using AL-579 as a primary antibody and visualized using the Labeled Streptavidin-Biotin kit (Dako, Carpenteria, CA). Nuclei were counterstained with hematoxylin. Needle-core biopsies were also obtained for animals with potential rejection without meeting the requirements for humane euthanasia. Images were digitally scanned by using Aperio Scanscope AT Turbo (Leica Biosystems, Buffalo Grove, IL).
Statistical analysis
Statistical analyses were performed using Prism (GraphPad, La Jolla, CA). Analysis of ex vivo data were performed with two-way analyses of variance (ANOVAs). Allograft survival was compared by using Kaplan-Meier analysis (log-rank) of graft rejection. Longitudinal analysis of flow cytometry was performed by using two-way ANOVA. Histology scoring was compared by using a v 2 test.
Results
Activated HA LFA-1 is associated with CoBRR We first identified the specificity of AL-579 in rhesus splenocytes, lymphocytes, and PBMCs from healthy control animals ( Figure 2A ) and animals with CoBRR ( Figure 2B ) using flow cytometry. As expected, we found that HA LFA-1 as detected by AL-579 was present at very low levels in healthy animals. Conversely, the frequency of AL-579-positive T cells were markedly higher in animals with CoBRR. As expected, AL-579-positive cells were not detected in peripheral blood or lymph nodes, but a significant proportion of graft-infiltrating lymphocytes expressed HA LFA-1. We also compared binding of AL-579 to a selective LFA-1 antibody that favors the low-affinity conformation of LFA-1. This confirmed in our model that AL-579 does bind a subset of T cells that differs from low-affinity LFA-1 selective binding. Comparison of this rejection phenotype histology from a rejection during conventional triple therapy (consisting of tacrolimus, mycophenolate mofetil, and steroids) again stained with AL-579 and further suggests this to be a accentuated in CoBRR. These data support the involvement of HA LFA-1 in CoBRR and the potential for specific adjuvant therapy to CoB.
LtxA effectively depletes CD8 + T EM and natural killer cells LtxA has been shown to effectively deplete malignant leukocytes with high expression of the activated LFA-1 conformation (36). We therefore sought to examine the efficacy of LtxA-mediated leukocyte and lymphocyte toxicity in our NHP model. Using na€ ıve NHP peripheral blood, we introduced increasing doses of LtxA ex vivo and measured cells with flow cytometry for white blood cell and T cell markers in combination with 7AAD and annexin V cell death markers ( Figure 3A) . Initial findings demonstrated a significant dose-response effect for CD8 naive T cells (TN) or central memory T cells (TCM) with a greater effect on CD8 T EMs (p < 0.01, Figure 3B ). We next tested the effect of activation-induced LtxA cytotoxicity on PBMCs. We found that natural killer (NK) cells, in addition to CD4 and CD8 T cells, were more susceptible to LtxA after treatment with PMA/ionomycin (p < 0.01, Figure 3C ). On closer examination of memory subsets as defined by CD95 and CD28, T EM cells appeared to be depleted in a dose dependent fashion without a requirement for chemically induced activation, although PMA/ Ionomycin further increased this effect (p < 0.01, Figure 3D) . To confirm these effects in vivo, we then administered LtxA to three different na€ ıve rhesus macaques and measured the peripheral counts using flow cytometry at set time points up to 168 h after administration. Figure 3D illustrates similar depletion in vivo of NK cells, T cells, and CD8 + T EM cells compared with ex vivo observations. These data reveal a substantial depletional effect with LtxA administration that favors NK and T EM cells, the latter suggesting this agent as another potential adjuvant therapy for CoB.
Adjuvant depletion or blockade of HA LFA-1 does not improve CoB therapy in an NHP model
Having demonstrated the effects of both LtxA and AL-579 in vitro and in vivo, we next examined these agents in a well-described NHP model of renal transplantation. We administered these agents in conjunction with belatacept to assess the potential synergistic effect of blocking or depleting activated LFA-1 on T EM cells, which can be indifferent to CD28:B7 blockade alone. In first examining the effects of LtxA with COB, we found that LtxA administration after renal transplantation at two different doses did not improve allograft survival over CoB alone ( Figure 4A ). While LtxA given as a monotherapy did not provide any additional survival benefit over no treatment, LtxA given at 15 µg/kg doses after transplantation in conjunction with belatacept led to rapid allograft loss with only marginal improvement over LtxA alone (p = 0.08). Interestingly, this addition of low-dose LtxA significantly worsened allograft survival compared with belatacept alone (p = 0.04). LtxA given at an intermediate dose (25 µg/kg) in conjunction with belatacept did not improve or worsen survival over belatacept alone. When LtxA was given at a higher dose of 75 µg/kg, both recipients experienced significant toxicity, requiring removal from the study.
Next, we examined AL-579 in conjunction with belataceptbased CoB. As illustrated in Figure 4B , the addition of AL-579 to belatacept did not improve allograft survival compared with belatacept monotherapy (p = 0.86). The inclusion of targeted HA LFA-1 depletion or blockade in our renal transplant model ultimately did not provide further benefit to CoB-based immunosuppression.
Minimal changes in immunophenotype during treatment with AL-579
Our prior study inhibiting all conformations of LFA-1 in a renal transplant model demonstrated an increased peripheral lymphocytosis, which diminishes during the tapering of LFA-1-inhibiting agent (22) . The short induction course of AL-579 did not affect peripheral white blood cell or lymphocyte counts ( Figure 5 ). Further examination of peripheral T cells by using flow cytometry demonstrated similar frequencies of CD8 T EMs ( Figure 6 ). 
Regulatory T cells defined as CD25 + CD127
FoxP3 + CD4 + cells were also similar in frequency in the peripheral blood (data not shown). Banff scoring of rejected allografts in AL-579-treated and control group animals suggested a strong trend that AL-579 treatment prevented vasculopathy and glomerulopathy during rejection (Table 1 and Figure 7 , p = 0.09). Serum CMV viral copies did not differ greatly between the two treatment arms. However, an increase in CMV viral copies occurred at the peak of AL-579 treatment and reduced to normal levels as this agent was tapered without any additional treatment (data not shown).
Discussion
Belatacept has been introduced as an alternative to CNIbased transplantation immunotherapy. The advantages of this biologic include the reduction of off-target side effects, which are problematic and common with CNI use. These CNI-associated complications have largely motivated further understanding of CoBRR to optimize the application of belatacept and leverage its benefits for transplant patients. The evasion of T EM cells to the effects of belatacept have led to further studies and trials targeting T EM cells to identify adjuvant therapies that facilitate CD28:B7 blockade (7). Data obtained from rejected NHP kidneys in the described model demonstrated CoBRRspecific involvement of HA LFA-1-expressing lymphocytes within rejected allografts. The implication of this distinct signature led us to hypothesize that blocking function of the more relevant conformation of LFA-1 would protect against intragraft migration and effector function. In these studies, we applied highly selective agents targeting HA LFA-1 in an NHP renal transplant model to further explore this modality of CoB adjuvant therapy. We find, however, that despite evidence of in vitro and in vivo efficacy, the addition of neither LTxA nor AL-579 in these studies was able to improve on belatacept monotherapy alone. These data, in addition to prior and ongoing studies, highlight the difficulty in targeting T EM cell-specific surface markers in relevant preclinical models.
Critical to the function of differentiated T cells are their interactions with lymphoid or vascular endothelium with migration into the lymph nodes or peripheral tissues, respectively. This process is dependent on the function of adhesion molecules such as LFA-1 and VLA-4 (37). LFA-1 in particular demonstrates a unique cell surface localization of high and intermediate conformations during endothelial migration (27) , with the HA conformation necessary for intercellular adhesion (23) . This conformational change is also seen during TCR engagement and T cell activation, serving to stabilize the immunologic synapse (38) . Earlier studies identified the necessity of LFA-1 in migration via CD2-and T cell receptordependent mechanisms (39, 40). It is important to note, however, that the current data available have not clarified the function of the various affinity conformations of LFA-1 in T EM cell migration or activation (26) . The current understanding of CoBRR and the implication of T EM cells offered a unique opportunity to assess specifically the significance of HA LFA-1 in the alloreactive T EM cell response seen in CoBRR.
In this study, an appropriate therapeutic window for LtxA to achieve an immunosuppressive effect while avoiding serious toxicity was not identified. Our initial in vivo study demonstrated that a single dose of IV LtxA in healthy animals was sufficient to transiently deplete lymphocytes from the circulating population. However, in the setting of immune activation via surgical laparotomy and allogenic solid organ transplantation, we hypothesized that of the behavior LtxA might be less predictable. The three initial animals that were given LtxA monotherapy were each given different doses in an effort to determine a therapeutic dose. However, these animals all rejected with the same kinetics as untreated controls. These animals demonstrated allograft pathology consistent with rejection with no clinical evidence of side effects. Therefore, the next cohort of animals combined belatacept with higher doses of LtxA, again seeking a potential therapeutic window for LtxA. The intermediate dose (25 µg/kg) appeared to have no effect, while, interestingly, the low-dose LtxA (15 µg/kg) significantly worsened allograft survival. Attempting a higher dose of LTxA (75 µg/kg) resulted in significant toxicity, necessitating the removal of two animals from the study. We hypothesize that high-dose LtxA treatment may have precipitated rapid lymphocyte lysis in the setting of surgical trauma and inflammation resulting in physiologic signs analogous to a tumor lysis phenomenon. Therefore, despite the desired ex vivo and in vivo effects, application of HA LFA-1-based depletion may be not efficacious in the setting of a solid organ transplant.
The alternative strategy of HA LFA-1 blockade (without depletion) in conjunction with CoB was also explored in this transplant model. However, inclusion of AL-579 adjuvant therapy to a belatacept-based regimen had no obvious benefit over belatacept alone. Study of circulating PBMCs through the transplant period demonstrated no major differences in leukocyte or lymphocyte count, although given the transient expression of HA LFA, no peripheral or bulk phenotype was anticipated (30, 34) . This is in contrast to our previous finding using agents broadly directed against LFA-1, in which peripheral lymphocytosis paralleled the dose of anti-LFA-1 given at the time (22) . This particular finding may illustrate the limited significance of HA LFA-1 in margination and migration in this scenario or the inability of systemically distributed antibody therapy to sufficiently interrupt the very transient and local expression of HA-LFA-1. Circulating T EM cell populations were also unchanged with the addition of AL-579. Histologic data during AL-579 treatment suggested that this interaction may be involved in rejectionassociated vasculopathy, suggesting some level of anti-inflammatory effect. Regardless, this possible lack of vascular involvement did not ultimately preserve allograft function from rejection. These data in combination with the incorporation of LtxA in our transplant model ultimately demonstrate that HA LFA-1 may not be an efficacious target for CD28:B7 blockade adjuvant therapy. Of note, our control group in the AL-579 study appeared to have better outcomes than the control group from the LtxA study; this observation is likely a result of each control and experimental group being performed at two institutions with different belatacept dosing after POD 180, a time point irrelevant to this study. Nevertheless, it underscores the value of continued belatacept dosing late after transplantation.
Although our initial data were associated with a unique phenotype of HA LFA-1 involvement in CoBRR, the lack of any benefits seen with either blockade or depletion of HA LFA-1 may be explained through several possibilities. The conformational changes of LFA-1 are required in the priming and proliferation of na€ ıve T cells (26) , but T cell receptor engagement alone does not induce greater expression of HA LFA-1 without the presence of insoluble ICAMs (41) . Additionally, the rapid flux of LFA-1 conformational shifts may significantly narrow the temporal window where an effect may be observed in this model (42) . These observations suggest that T EM cell dependence on HA LFA-1 for activation may be limited in the setting of antigen presentation, although further study would be warranted. Mice with genetically modified LFA-1 to maintain a persistent activated state acquire significant immunologic defects in regard to T cell activation and migration (43) , underlining the complex regulation of LFA-1 affinity required for normal immune function. Examination of ICAM interactions in a murine model demonstrated its necessity for T cell priming and activation, but the lack of ICAM on transplanted allografts did not prevent alloreactive T cell infiltration and subsequent rejection (44) . With the redundant presence of adhesion molecules on immune cells and their target proteins, it is very likely that migration is not dependent solely on LFA-1. Indeed, VLA-4 may play a more significant role for alloreactive CD4 T cell intragraft migration (13, 45) . Additionally, prior studies examining adhesion blockade in transplantation may not necessarily distinguish its effects on the immunologic synapse versus memory T cell effector function. These data in addition to prior NHP studies (22) suggest that alloreactive memory T cell function, particularly intragraft migration and subsequent injury, is not dependent on LFA-1 in either the intermediate-affinity or HA state.
These studies examining HA-LFA-1 in CoBRR, in addition to prior and ongoing preclinical trials in this domain, further contribute to the evidence against targeting T EM cellspecific surface markers to abrogate CoBRR. Prior studies with demonstrable efficacy against T EM cells through surface marker targeting have also demonstrated some loss of protective immunity. Targeting belatacept-resistant T EM cells may either require more creative strategies to redistribute or redefine one's T EM cell repertoire in order to suppress alloreactivity and maintain protective immunity. T EM cells possess unique traits acquired along the process of their differentiation outside of their surface protein expression, such as metabolic and functional properties, which may offer these additional opportunities (37) . Additionally, further refining the etiology of CoB resistance, whether through more specific cell subtype definition or molecular mechanisms, will elucidate potential adjuvant strategies.
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Additional Supporting Information may be found in the online version of this article. Figure S1 : Derivation of AL-579 from AL-57. (A) The AL-579 c4 heavy chain is identical to the AL-57 heavy chain except it incorporates F-to-Y and I-to-S substitutions (indicated) found in a higher-affinity variant, C09, of AL-57. It also contains an M-to-L substitution to remove an exposed, oxidation-prone methionine, and an S-to-P substitution (indicated) in the c4 hinge to prevent heavy chain exchange among IgG4 molecules. (B) AL-579 j light chain is identical to the AL-57 light chain.
